The primary objectives of this study are to evaluate the safety and tolerability and determine the maximally tolerated dose of humanized monoclonal antibody Hu1D10 administered to patients with previously treated non-Hodgkin's lymphoma expressing the antigen recognized by 1D10 and to measure pharmacokinetics to compare pharmacology at different dose levels and determine the optimal biological dose of Hu1D10.
Showing the most recent 10 out of 381 publications